What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Oslo
- Enrollment
- 168
- Locations
- 7
- Primary Endpoint
- Number of days until symptomatic resolution
Study Overview
Brief Summary
The prevalence of extended spectrum beta-lactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades.
The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents.
Samples are gathered in primary care setting.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients were urinary sample taken in a primary care setting shows significant growth of ESBL producing E. coli.
- •Above age 16.
Exclusion Criteria
- •Sample from patients in hospital care or living in nursing home facilities. Inability to understand and sign information leaflet.
Outcomes
Primary Outcomes
Number of days until symptomatic resolution
Time Frame: Two weeks after finishing the primary antibiotic treatment
Number of days from the start of treatment that the patient feels completely free of urinary tract symptoms Number of days after start of antibiotic treatment with mecillinam when the patient feels free of symptoms from the urinary tract
Secondary Outcomes
- Number of patients with ESBL producing bacteria detected in a urine sample taken two weeks after finishing initial treatment(Two weeks after end of initial treatment)
- Number of patients who received a second treatment regime in the follow-up period(2 weeks after end of initial treatment)
Investigators
Marianne Bollestad
MD
University of Oslo